Purpose: Using bibliometrics, we analyzed the research status of immune checkpoint blockade (ICB, a popular tumor immunotherapy method represented by antibodies targeted CTLA-4 and PD-1/PD-L1) in tumor immunotherapy in China during the past 2 decades.
Introduction
Cancer is one of the leading causes of death in the world, trailing just behind cardiovascular diseases. [1, 2] Traditional strategies for cancer treatment include surgery, chemotherapy, and radiotherapy. However, these methods have serious side effects and many patients succumb to cancer due to metastasis. Targeted therapy is more specific, but drugs that are effective for cancers with the target gene mutations often have poor therapeutic effects on cancers with other gene mutations. [3] This means targeted drugs can only be used to treat certain types of cancer. In Comparison with traditional methods, tumor immunotherapy, including immunomodulator, tumor vaccine, adoptive cellular immunotherapy, and immune checkpoint blockade (ICB), can modulate the host immune system and enhance antitumor response. [4] [5] [6] [7] Encouragingly, after decades of efforts, tumor immunotherapy has made significant progress and gained recognition in the field of tumor therapy. For instance, adoptive cellular immunotherapy and ICB in tumor therapy were recognized as some of the biggest breakthroughs of the year in 2013 by Science Magazine. [8] One of the most important advancements in tumor immunotherapy, ICB, is based on our understanding of the interactions between T cells and tumor cells. [9] T cells are the principal immunological force in the war against tumors. [9] Interaction between B7-1 (CD80)/B7-2 (CD86) proteins on the surface of antigen presenting cells (APCs) and CD28 on the surface of T cells (a costimulating signal) is required for the T cell activation. However, T cell activation gradually leads to the expression of checkpoint molecules such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death 1 (PD-1), which acids to avoid aberrant T cell activity. [10] [11] [12] Expressed only on activated T cells, CTLA-4 has a higher affinity for B7 than CD28, and can inhibit the costimulating signal, thus reducing the T cell-dependent antitumor effect. [13, 14] PD-1 (a member of B7 family) can be expressed on activated T cells and the ligand of PD-1 (PD-L1) is highly expressed on both APCs and tumor cells. [15] The interaction of PD-I and PD-L1 eventually results in T cell apoptosis, anergy, and exhaustion. [16, 17] Therefore, drugs that inhibit CTLA-4 and/or PD-1/PD-L1 activity enhance the antitumor immunity response via ICB. The anti-CTLA-4 drug YERVOY (Ipilimumab) has been approved by the American Food and Drug Administration (FDA) as a first-line therapy for advanced melanoma. [18] In the last 2 decades, numerous studies on immune checkpoint blockade for tumor immunotherapy have been published. Effective way, such as bibliometrics, is needed to summarize and analyze these research advances and obtain a view of research status of ICB in tumor immunotherapy in China.
Through statistical analysis of the literature, bibliometrics describes, evaluates, and forecasts the status and development of trends in science and technology. [19] Bibliometrics are widely used in clinical research, as they provide reference data that can be used to understand the dynamics of technology, determine the novelty of projects, publicize research results, and make decisions on which scientific topics to study. [19] To date, bibliometrics have been used in evaluating and forecasting trends of macrohealth science and medical systems in the fields of cancer, Alzheimer's disease, and diabetes, and micro-fields such as tumor biomarkers. [19] [20] [21] [22] However, very few literature studies have reported on the overall research status in the field of immune checkpoint blockade in tumor immunotherapy. Information on how Chinese research in this area is compared with the global community is especially lacking. Therefore, we took advantage of databases in the Shanghai Information Center of Life Science of the Chinese Academy of Sciences, and performed both qualitative and quantitative analyses of the articles, patents, and drugs produced in the field of immune checkpoint blockade from 1996 to 2015 both worldwide and in China. We identified a rapid expansion of publications and patents from China in immune checkpoint blockade research during the last 2 decades, but also found shortcomings in these studies. Our results provide a better understanding of the research status of tumor immunotherapy and offer a reference for relevant future research in China.
Materials and methods

Data sources
Published data from the Shanghai Information Center of Life Sciences of the Chinese Academy of Sciences were used for our analyses. We chose the science citation index expanded (SCIE) from the database of Institute of Scientific Information (ISI) Web of Science TM as data sources in the last 2 decades (from 1996 to 2015). The impact factors reported are from the 2014 database of ISI Web of Knowledge Journal Citation Reports (updated in June, 2015).
Index strategies
Global immune checkpoint blockade research: subject term= ("CTLA-4" OR "Cytotoxic T lymphocyte antigen-4" OR "CD152" OR "PD-1" OR "Programmed death 1" OR "CD279" OR "PD-L1" OR "programmed death-ligand 1" OR "CD274" OR "B7-H1") SAME (cancer OR tumor) AND publication year= (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) . Refining basis: paper type=article.
CTLA-4 target tumor immunotherapy research: subject term= ("CTLA-4" OR "Cytotoxic T lymphocyte antigen-4" OR "CD152") SAME (cancer OR tumor) AND publication year= (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) . Refining basis: paper type=article.
PD-1/PD-L1 target tumor immunotherapy research: subject term= ("PD-1" OR "Programmed death 1" OR "CD279" OR "PD-L1" OR "programmed death-ligand 1" OR "CD274" OR "B7-H1") SAME (cancer OR tumor) AND publication year= (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) . Refining basis: paper type=article.
Immune checkpoint blockade research in China: subject term= ("CTLA-4" OR "Cytotoxic T lymphocyte antigen-4" OR "CD152" OR "PD-1" OR "Programmed death 1" OR "CD279" OR "PD-L1" OR "programmed death-ligand 1" OR "CD274" OR "B7-H1") SAME (cancer OR tumor) AND publication year=(1996-2015) AND address=(Peoples R China). Refining basis: paper type=article.
Using the above indexing strategies, we analyze research papers in the areas of melanoma, myeloma, lymphoma, lung cancer, prostate cancer, and pancreatic cancer in China or around the world. 
Data collection
Results
China plays an important role in the world in the research on ICB for tumor immunotherapy
From 1996 to 2015, 2648 papers on ICB for tumor immunotherapy were published worldwide. China published 380 papers, accounting for 14.3% of all publications, and ranking second behind the USA. China produced more papers than Germany, Japan, and France. However, China had room for improvement in terms of article influence. For example, in the top 10 countries or districts, China ranks the lowest for the average citations per paper (ACPP), and 7 th place in the h-index (high citation index), an indicator for influence of the papers (Fig. 1) .
In terms of timing, the number of publications from China in ICB for tumor immunotherapy increased rapidly in last decade compared with the previous decade. There were only 13 papers (Table 1) .
The number of publication in China increases annually
A total of 70 papers in the field of ICB for tumor immunotherapy were published during 2006 to 2010 (12.2%) from China. This increased to 296 papers published between 2011 and 2015 (17.5%), indicating that China made significant progress in contributing to tumor immunotherapy research. The average annual growth rate of Chinese publications was 33.0% during the past decade, while the global average was 27.0%, and the USA average was 24.1% (Table 2) . We predict that in the next 5 to 10 years China will produce more researches in the area of tumor immunotherapy.
Top 10 institutions in the field of ICB for tumor immunotherapy research
The top 10 institutions publishing research in ICB for tumor immunotherapy from 1996 to 2015 were all from the USA except 1 institute from France (#8, INSERM). The top 3 institutions were Harvard University, VA Boston Healthcare System, and Dana-Farber Cancer Institute. Suzhou University (#29) had the most publications in China. However, in terms of ACPP and hindex, Suzhou University showed a significant lag behind institutes of the USA (Fig. 2) . The top Chinese contributors to this research were Universities, except for the Chinese Academy of Sciences (#6). The total number of published papers in the first 10 years (2006 to 2015) was almost same as that in the full 20 years (1996 to 2015), revealing that the publication contributions from China were mostly made in the last 10 years (Table 3) .
Highly cited papers
There were 3 highly cited papers (HCP) that were published in 2011, 2014, and 2015 from China, which were from Suzhou University, Fudan University, and Sichuan University, respectively. China's HCP (3) is 1.8% of the global HCP, while the USA's HCP (140) is 82.8% of the global HCP ( Table 4 ), indicating that China still lags a significant behind in terms of high quality papers at the global standard.
Funding in China primarily comes from the national natural science fund
Funding sources on ICB for tumor immunotherapy generally came from the National Natural Science Foundation of China (NSFC) and the 973-National Basic Research Program of China plan (Table 5) . The main application of tumor immunotherapy in China was on lymphoma, lung cancer, and pancreatic cancer. The USA exhibited major advantages in melanoma, myeloma, lymphoma, lung cancer, prostate cancer, and pancreatic cancer. Blockade of CTLA-4 has been primarily used to treat melanoma, lymphoma, lung cancer, and prostate cancer in China, whereas it has been largely used to treat melanoma, prostate cancer, and pancreatic cancer in the USA. Blockade of PD-1 has been primarily used to treat melanoma, lymphoma, and lung cancer, with fewer treatment attempts for myeloma, prostate cancer, and pancreatic cancer in China, whereas it has been used with a focus on melanoma, myeloma, and prostate cancer in the USA (Table 6 ). (Fig. 3) . Among the top 20 organizations generating global public patents, Suzhou M Conj Biotech Co Ltd. is the only Chinese company (Table 7) . Among the top institutions generating public patents, Univ Zhengzhou (the University of Zhengzhou) of China ranked No. 6 (Table 8) . Among the drugs that targeted PD-1, 4 drugs were from China. China had 2 original research and development institutes, while there were 24 in the USA, 5 in the UK, 2 in Germany, 2 in India, 1 in France, and 1 in Australia (Table 9 ). In addition, 33 drugs was currently being developed in the world, including 3 in China, 17 in USA, 7 in UK, 2 in Germany, 2 in India, 1 in France, and 1 in Japan (Table 10 Melanoma  931  56  577  586  20  365  477  38  297  Myeloma  47  4  22  19  0  9  33  4  16  Lymphoma  285  34  124  74  12  34  228  23  101  Lung cancer  269  64  121  104  19  48  203  52  96  Prostate cancer  175  15  136  134  11  108  71  7  50  Pancreatic cancer  70  18  33  27  5  17  53  13  23  Total  1,777  191  1,013  944  67  581  1,065  137  583 Note: ("CTLA-4" OR "Cytotoxic T lymphocyte antigen-4" OR "CD152") SAME (cancer OR tumor): 1035. ("PD-1" OR "Programmed death 1" OR "CD279" OR "PD-L1" OR "programmed death-ligand 1" OR "CD274" OR "B7-H1") SAME (cancer OR tumor): 1472. ICB = immune checkpoint blockade. At present, 2 PD-1 drugs were approved by US FDA. In 2014, Opdivo (Nivolumab) was firstly approved for patients with unresectable melanoma in Japan, and US FDA granted accelerated approval to it for patients with advanced melanoma. [23] In 2015, FDA expanded its application for patients with advanced renal cell carcinoma. [24] Then, it was approved for the treatment of patients with head and neck squamous cell carcinoma (SCCHN) in November 2016 [25] and for advanced urothelial carcinoma in February 2017. [26] Keytruda (Pembrolizumab) was approved by the FDA for treatment of unresectable or metastatic melanoma in 2014. [27] It is the first PD-1 inhibitor approved by FDA. In 2015, it was approved as the first-line treatment of advanced melanoma. [28] In 2016, it was approved for first-line therapy for advanced non-small cell lung cancer (NSCLC) patients with high expression (more than 50%) of PD-L1. [29] In 2017, it was approved for unresectable or metastatic, microsatellite instable-high (MSI-H), or mismatch repair-deficient (dMMR) solid tumors. [30] Overall, China has made progress developing drugs for ICB for tumor immunotherapy, but the number of effective drugs is still lower than those produced in the USA and UK.
Discussion
Immune resistance in tumor microenvironment makes it hardly trigger effective immune response for tumor antigens. As the core executor of anti-tumor response, T cells were firstly activated by the capture of tumor antigens by TCR and regulated by a range of costimulation signals and coinhibition signals. These coinhibition signals are immune checkpoints that facilitate the maintenance of immune tolerance and the inhibition of autoimmune responses. Tumor cells can escape immunosurveillance by upregulating coinhibition signals and suppressing T cell activities. Therefore, T cell activation, induced by methods such as ICB, are critical for cancer therapy. Indeed, after decades of effort, ICB made great progresses in cancer immunotherapy, and have gradually been applied in clinic. Here, we used the bibliometrics method to provide a comprehensive overview of research status of ICB in tumor immunotherapy in china and worldwide during the past two decades. Notably, the number of papers about ICB in China increased rapidly in the past 2 decades, especially in the recent 10 years that increased from 13 to 366, and the total number of papers (379) just lay behind USA. In addition, the average annual growth rate of Chinese publications was 33.0% during the past decade, which is above the global average (27.0%) and the USA average (24.1%). However, greater efforts are needed to improve the quality of ICB papers from China. For instance, though the hindex increased from 6 in 2006 to 2015 to 30 in 2006 to 2015, China still ranks the lowest for the ACPP and 7 th place for the hindex during the past 2 decades in the top 10 countries. Similarly, in terms of HCP, China's HCP (3) is 1.8% of the global HCP Table 9 Institutes that are engaged in originally designing ICB drugs.
Institutes
CTLA-4 PD- 1   USA  14  24  China  4  2  United Kingdom  2  5  Germany  2  2  Switzerland  2  0  Japan  2  0  India  2  2  France  1  1  Sweden  1  0  Australia  0  1  Total  30  37 CTLA-4 = cytotoxic T-lymphocyte antigen 4; ICB = immune checkpoint blockade; PD-1 = programmed death 1. The potential reasons for the rapid development of China's tumor immunotherapy research may include the following: first, Chinese GDP maintained double-digit growth since 2000 and the medical industry income kept a 20% growth rate for the past 10 years. In addition, the pharmaceutical industry experienced strong development as well. Second, the steady increase in government investment in drug development contributes to the rapid growth of ICB for tumor immunotherapy research in China. The Chinese public financial investment in health insurance increased since 2004 when Beijing allowed health insurance to cover tumor immunotherapy. Total funding by the National Natural Science Foundations of China (NSFC) grew rapidly, and NSFC has devoted 20.71 million Chinese Yuan (RMB) to 60 projects since 2000. There was also a significant amount of funding from national special research fundings, such as "863" and "973" projects, and some local committees of science and technology. Meantime, this increase in research quality attracted funding from institutes of foreign countries, such as the National Institute of Health (NIH) of USA. However, the funding is still not adequately in line with the brisk growth of China's national gross domestic product (GDP), the growing and aging population, and the urgent health needs of cancer patients. To continue improving the quality and global influence of Chinese research on tumor immunotherapy and to promote translational research and precision therapy, a persistent increase of investment from governments, including the central and local governmental agencies, will be imperative. In addition, the financial support from non-government sources needs to be enthusiastically developed.
To conclude, ICB has developed rapidly with increasing influence in the last 2 decades in China. However, there is still a relatively large gap compared with the USA. This work represents the first bibliometric assessment of research quantity and quality in ICB literature. However, there are several limitations of the present study. Firstly, all the papers we collected were from PubMed database, while the papers from other databases and Chinese journals are not included. Secondly, the drugs for ICB we searched are focused on CTLA-4 and PD-1/PD-L1, while drugs target for other immune checkpoint molecules are lacking. Finally, all the data were only dated back to 1996.
